Transgene-encoded therapeutic secretory proteins can be efficiently secreted from salivary glands into saliva or the bloodstream after adenoviral (Ad)-mediated gene transfer. Since transgene expression from conventional vectors is typically unregulated, we evaluated the rapamycin-based dimerizer regulation system for control of transgene expression in, and consequent exocrine protein secreted from, rat salivary glands. We used human growth hormone (hGH) as a surrogate exocrine secretory protein. Two Ad vectors, Ad C4ZF3, encoding activation and DNA binding domain fusion polypeptides, and Ad Z12-I-GH-2, encoding hGH, were constructed and shown useful in vitro. Thereafter, both vectors were delivered into submandibular glands by retroductal infusion. After 24 h, rapamycin (0, 1, 3 or 10 mg/kg) was administered, and 20 h later hGH levels in saliva were determined. Salivary hGH levels were rapamycin concentration dependent. At a rapamycin dose of 10 mg/kg, total salivary hGH was 6937197 ng and the hGH concentration in saliva was 4.671.3 mg/ml. Over a 16-day experimental period, three separate administrations of rapamycin (3 mg/kg) induced distinct elevations of salivary hGH (B100-200 ng total hGH) that were entirely rapamycin dependent. This study demonstrates for the first time pharmacological control of transgenic exocrine protein production and presence in saliva after salivary gland gene transfer, and the potential for its application to the management of oral, oropharyngeal and upper gastrointestinal tract disorders.
Salivary glands are secretory organs, capable of secreting substantial amounts of protein both into saliva (exocrine) and into the bloodstream (endocrine). These tissues have proven to be useful target sites for delivery of genes encoding therapeutic proteins. 1, 2 Salivary glands can be accessed noninvasively by intraoral cannulation of the main excretory ducts. Effective gene transfer into salivary cells has been achieved with both adenoviral (Ad) 3 and adenoassociated viral 4 vectors. As in many other well-differentiated eukaryotic cells, secretory proteins expressed in salivary gland cells follow one of two main pathways for secretion; constitutive or regulated. 5, 6 Salivary glands consist of polarized epithelial cells, from which transgene-encoded proteins using the constitutive pathway are primarily secreted basolaterally into the bloodstream, while those taking the regulated pathway are secreted apically, into saliva. 1, 2 For novel treatments of oral, oropharyngeal and upper gastrointestinal tract disorders, salivary glands may be particularly useful as gene transfer targets versus more distal systemic gene delivery sites. 7 Transgene expression with conventional gene therapy vectors is unregulated and continuous. For clinical use, this could result in both protein expression well beyond the therapeutic range, as well as an unsatisfactory delivery schedule. 8, 9 As a result, there has been much effort to control the time and extent of therapeutic protein expression following gene transfer. One system that has shown promise for this purpose is termed dimerizer-mediated gene regulation, and is based on transcriptional control of the transgene by rapamycin or a derivative drug. 8, 9 With this system, the DNA-binding and activation domains of a chimeric transcription factor are produced as separate polypeptides, each fused to the drug-binding domain of the human proteins FKBP or FRAP. 8 In the presence of rapamycin, these two components can form a heterodimer, thus reconstituting a functional transcription factor. In the first generation of this system, two vectors are used. One encodes both the activation domain and the DNA-binding domain, separated by an internal ribosome entry site, while the other encodes a transgene downstream of an engineered binding site for the DNA-binding domain and a minimal promoter. [8] [9] [10] The rapamycin-based transcriptional control system has proved useful in several diverse tissues, including muscle, 10, 11 liver, 12 and eye. 13 We are unaware of any reported applications of this dimerizer system to, or any other system regulating gene expression of, exocrine secretory proteins. The purpose of the present study was to determine if the rapamycin-based system was useful to control the levels of a model-regulated pathway secretory protein found in saliva.
For this proof of concept study, we chose human growth hormone (hGH) as a model exocrine protein.
When expressed in salivary glands, hGH primarily is secreted through the regulated pathway in an exocrine manner into saliva. 2 Importantly, hGH has a short half life in rats (protein B45 min; 2 mRNA B1.5 days), 14 rendering it a reasonable candidate gene to be studied using Ad vectors over a 2-week period. We constructed two recombinant, E1 À , type 5 Ad vectors. AdC4ZF3 contained the two components of the chimeric transcription factor, while AdZ12-I-GH-2 encoded hGH.
Initially, we used these two Ad vectors in vitro to examine the effects of the dimerizer drug on hGH expression. For these studies, we used A5 cells, a rat submandibular gland cell line. 15 After infection with AdC4ZF3 and AdZ12-I-GH-2 (1:1) at an MOI of either 100 or 200 particles/cell, dimerizer-regulated hGH expression was readily detected in culture media ( Figure  1 ). The expression of hGH was dependent on the presence of a rapamycin analogue (AP21967) over a wide dosage range and was most effective at concentrations Z10 nM. On average, maximum hGH production (48 mg/ml) was seen after 48 h with 100 nM dimerizer drug. Below 1 nM dimerizer drug, little secreted hGH was detected. In the absence of the dimerizer drug, hGH expression was less than the assay detection limit (0.02 ng/ml). These results are similar to previously published in vitro studies examining rapamycin (and its analogues) control of gene expression in other cell lines. 19 Next, rats were administered both viruses (1:1; 2 Â 10 11 total viral particles/submandibular gland) via retrograde salivary duct delivery, and 24 h later the animals were treated (intraperitoneal injection) with different doses of rapamycin (0, 1, 3, 10 mg/kg), based on previous in vivo studies with mice. 9, 10 Rapamycin was used for in vivo experiments (in place of AP21967) because of the amount of drug required. After 20 h, we stimulated the secretion of saliva with the parasympathomimetic drug pilocarpine. 2, 4, 7 As with the in vitro studies, we found that salivary hGH levels were dependent on the rapamycin dose administered (Figure 2 ). At the highest dose (10 mg/kg) of rapamycin used, the average total hGH found in saliva was 693 ng. This corresponds to an average salivary hGH concentration of 4.671.3 mg/ml, and is significantly greater than hGH levels at the two lower rapamycin doses used (3 mg/kg, P ¼ 0.029; 1 mg/ kg, P ¼ 0.022). At 1 mg/kg, the average concentration of hGH in saliva was B1.5 mg/ml, while at 3 mg/kg the average salivary hGH concentration was B2.1 mg/ml. Interestingly, at this latter dose, the average total amount of hGH found in saliva was 323 ng and in serum was B17 ng (a 19-fold difference; similar to results previously reported).
2 Importantly, in the absence of the dimerizer drug, there was no detectable hGH in saliva or serum, that is, below the assay detection limit.
Finally, we wished to determine if rapamycin's presence could regulate hGH expression over time in Figure 1 Rapamycin analogue-dependent hGH production in vitro in A5 cells. The EcoR I/BamH I fragment of the bicistronic transcript from the plasmid pC 4 N 2 -R H S3H/ZF3 (ARIAD Pharmaceuticals, Cambridge, MA, USA) was inserted directionally into pACCMV-pLpA. 16 A cassette containing the hGH cDNA was cut with Mlu I and BamH I from pZ12-I-hGH-2 (ARIAD Pharmaceuticals), blunted and then inserted into pACCMV-pLpA after it had been cut with Not I and blunted. Plasmid structures were confirmed by restriction enzyme digestion and by AP21967-induced hGH production after transient transfection of A5 cells. Recombinant, E1
À Ads were generated and purified by standard methods. 16, 17 The vectors were screened for replication-competent Ad by a quantitative PCR (QPCR) assay, essentially as described. 18 The assay amplified the Ad E1 gene using the plasmid pBHG10 (Microbix Biosystems, Toronto, Canada) as negative control. The primers used in this QPCR assay were as follows: forward primer, CTT GAG TGGCAG CGA GTA GAG TT, and reverse primer, TAT GTC TCA TTT TCA GCA GTC CCG GT. The Ad vectors used herein gave results with this assay that were indistinguishable from the background obtained with pBHG10 (17.377.8 copies/10 7 molecules; t ¼ 0.025; P ¼ 0.98). A5 cells were cultured in McCoy's 5A media supplemented with 10% fetal bovine serum, at 371C with 5% CO 2 . Cells (5 Â 10 5 /well, 12-well plates) were infected with a mixture of viruses (1:1; at the indicated doses). After 24 h incubation, fresh media containing the rapamycin analogue AP21967 (ARIAD Pharmaceuticals) at the indicated concentrations was added to cells. hGH expression in the media was subsequently detected after 24 and 48 h using an hGH chemiluminescence immunoassay kit (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Assays were performed in triplicate, and the lower limitation of hGH detection was 0.02 ng/ml. Values of hGH shown are means ¼ (n ¼ 3). Atropine (100 ml, 0.5 mg/kg; Sigma, St Louis, MO, USA) was administered 10 min prior to retroductal infusion of viral vectors. AdC4ZF3 and AdZ12-I-GH-2 (1:1; 2 Â 10 11 total particles/gland) in 150 ml virus dilution buffer (pH 7.4-7.5, 5 mM MgCl 2 , 10 mM Tris, 20% glycerol) were infused. Rapamycin was initially dissolved in N, Ndimethylacetamide (DMA) to yield a stock solution, and shortly before use the stock was mixed with an equal volume of PEG-400 and Tween-80 (9:1). After 24 h, rats were injected i.p. with rapamycin at the indicated concentrations, or with vehicle, in a total volume of 600 ml. After 20 h, pilocarpine (5 mg/kg, subcutaneous injection, Sigma, St Louis, MO, USA)-stimulated whole saliva samples were collected for 20 min, placed on dry ice, and stored at À801C until gravimetric and hGH analyses. For the hGH assay, saliva samples were diluted as needed in TE buffer (pH 8.0). The background hGH level measured in naïve animals was subtracted from all experimental values. The data shown represent the concentration of hGH found in saliva (means 7 s.e.m.; n ¼ 4). Statistically significant differences are shown; (a) P ¼ 0.022; (b) P ¼ 0.029.
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J Wang et al salivary glands in vivo. Vectors were delivered to rat submandibular glands as above, and at various times thereafter rapamycin was administered intraperitoneally. For these studies, we used the intermediate dose of rapamycin (3 mg/kg). This dose is slightly less than that used previously to regulate hGH expression in murine muscle (5 mg/kg). 10 Saliva was subsequently collected on several days and the total amount of salivary hGH was determined. As shown in Figure 3 , we were able to induce three distinct elevations of hGH expression with the dimerizer drug over the experimental time course. At 20 h following the first administration of rapamycin, the total salivary hGH was 94736 ng. Thereafter, salivary hGH returned towards background levels. Two subsequent administrations of rapamycin led to two additional and distinct elevations of hGH in saliva, 177758 and 100749 ng, respectively. All three elevations in salivary hGH clearly corresponded with the previous administration of the dimerizer drug. Importantly, the control animals, that is, receiving the same dose of the two viral vectors per gland but no rapamycin, displayed no detectable salivary hGH. These results are similar to those previously observed for rapamycin induction of erythropoietin expression in serum in mice.
11
Our study demonstrates the potential utility of rapamycin-based regulation of transgene expression in salivary glands of immunocompetent rats with a modelregulated secretory pathway protein, hGH. The expression and appearance of hGH in saliva after stimulation with the secretogogue pilocarpine was responsive to, and dependent on, rapamycin administration. Rapamycin elicited hGH production in vitro and in vivo in a dosedependent manner. Control animals receiving both Ad vectors, but no dimerizer drug, displayed no detectable salivary hGH. Furthermore, rapamycin was able to induce similar elevations of hGH in saliva at three separate times over a 16-day experiment.
This latter finding suggests that most transduced salivary cells were able to survive during this time period and produce substantial amounts of hGH, a somewhat unexpected result based on our previous studies with first-generation Ad vectors. 20 Rapamycin is a potent immunosuppressive agent, inhibiting a wide spectrum of T-and B-cell activities. 21 These activities, in conjunction with the administration of dexamethasone to rats, which we used to blunt the adenoviral immune response, 1 may have contributed to the prolonged Admediated transgene expression seen herein. In an earlier study examining rapamycin-based regulation of hGH expression in muscle of immunocompetent Balb/c mice, utilizing Ad vectors similar to those employed herein, Rivera et al 10 were unable to elicit hGH expression following a second administration of the dimerizer drug. The present results may be a reflection of the immunologically different tissue environment in which gene transfer occurred.
As we have previously reported, following transfer of the hGH gene into salivary glands, hGH protein is primarily secreted into saliva, consistent with it being secreted in the regulated secretory pathway. 2 The total amount of hGH secreted into saliva is B10-25-fold greater than the total amount of hGH found in serum. 2, 22 Thus, despite its physiological role as an endocrine hormone, hGH serves as an excellent model for an exocrine secretory protein when expressed in a salivary gland. 2, 22 The concentrations of hGH measured in saliva were quite high, averaging B4.5 mg/ml following administration of the 10 mg/kg rapamycin dose. In general, the pattern of hGH expression in rat salivary glands is quite similar to that reported for immunodeficient mouse muscle by Rivera et al, 10 and likely reflect posttranscriptional events, such as mRNA decay rates rather than the clearance of rapamycin. 9 Many factors can affect the duration of transgene expression, including the type of vector used, the host response to the vector and the nature of the transgene. Ad vectors have been extensively used in preclinical, in vivo salivary gland gene transfer studies, because of their ease of production and because they can efficiently infect both dividing and nondividing cells. 1, [22] [23] [24] However, Ad vector expression in salivary glands, as in other tissues, 25 is typically short lived due to their induction of a potent immune response. 1, 20 Conversely, AAV-mediated transgene expression in salivary glands is long lived. 4, 26 The use of a dimerizer regulation system in the context of AAV vectors should permit extended control of transgene expression in salivary glands as it has in other tissues. [11] [12] [13] Our finding that rapamycin can regulate significant exocrine protein expression in salivary glands over a 16-day period suggests that dimerizer drug regulation may have applications for gene therapeutics in managing specific oral, oropharyngeal and upper gastrointestinal tract disorders. Indeed, the concentrations of the model exocrine transgenic protein (hGH), achieved in saliva (B1-5 mg/ml) herein, are consistent with two potentially valuable applications; for treating oral bacteria and fungal species that are resistant to conventional Figure 3 hGH appearance in saliva in rats after rapamycin administration. Rat submandibular glands were cannulated and the Ad vectors AdC4ZF3 and AdZ12-I-GH-2 (1:1) were infused into Wharton's duct at a total dose of 2 Â 10 11 particles/gland. Control animals received both Ad vectors, but no rapamycin, that is, they were injected with the DMA, PEG400 and Tween-80 vehicle. Rats also received a daily intramuscular injection of dexamethasone (1 mg/rat) during the first 4 days of this experiment. Arrows indicate the times of rapamycin administration. Pilocarpine-stimulated whole saliva samples were collected into preweighed 1.5 ml Eppendorf tubes at the days indicated (data points) and put in dry ice immediately until assayed exactly as in Figure 2 . The values of total salivary hGH shown are means7s.e.m. (n ¼ 6), and were calculated as previously described. 2 No detectable hGH was found in the saliva from control animals (not shown).
Rapamycin control of exocrine protein levels J Wang et al antibiotics and antifungals, respectively, and for enhancing the healing of oral ulcers.
For example, there is now considerable concern about the significant morbidity resulting from emerging antibiotic-resistant oral and oropharyngeal bacteria. [27] [28] [29] [30] Antimicrobial peptides encoded by single genes, such as the b-defensins, 31, 32 can be introduced into salivary glands by the gene transfer approach used here 7 and are effective in the 1-5 mg/ml concentration range. 31 Similarly, oral candidiasis is relatively common in immunosuppressed (AIDS, transplant) patients, 33, 34 and Candidal species are becoming increasingly resistant to azole-type drugs. 34, 35 Genes encoding anticandidal peptides, such as the histatins, 7,34 also can be readily introduced into salivary glands. Importantly, a typical course of antimicrobial therapy for oral infections would be for B10-14 days, that is, similar to that shown possible herein with Ad vectors.
Oral ulcerations, both those occurring iatrogenically (eg, following cytotoxic chemotherapy and therapeutic irradiation during the treatment for cancers), and those resulting from disease (eg, Bechet's syndrome), are common, painful and difficult to treat. Recently, preclinical and clinical studies have indicated that certain growth factors (eg, keratinocyte growth factor, 36 basic fibroblast growth factor; 37 epidermal growth factor 37 ) and cytokines (eg, interleukin-11; 38 interferon-a 2a 39 )may be beneficial for treating these ulcerative conditions. The recombinant growth factors or cytokines were delivered in these studies either by frequent topical application or injection. The therapeutically required concentrations of these proteins are much lower than those achieved in the present study (eg, ng/ml). Controlled expression of the genes for such proteins would require a time course similar to that shown herein, likely be much less expensive, and provide much higher local bioavailability than achieved by the conventional protein delivery methods.
In conclusion, our data show that effective and repeatable rapamycin-regulated hGH expression, and consequent appearance in pilocarpine-stimulated saliva, can be achieved using Ad vector delivery of the required regulatory components to salivary glands in vivo. The expression of hGH is dependent on the time and dose of rapamycin administration, and no hGH is detected in saliva in the absence of the dimerizer drug.
